Skip to main content

Table 1 Baseline characteristics for the examined early rheumatoid arthritis patients. Results are given in mean (± standard deviation) for continuous variables and numbers (percentages) for categorical variables.

From: Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study

 

Adalimumab +

Methotrexate

(N = 214)

Methotrexate

Monotherapy

(N = 188)

Demographic characteristics

  

Age (years)

51.8 (14.3)

52.6 (13.2)

Female %

152 (71.0)

137 (72.9)

Clinical characteristics

  

Disease duration (years)

0.7 (0.8)

0.8 (0.9)

Previously taken DMARDs %

69 (32.2)

56 (29.8)

Previously taken corticosteroids %

79 (36.9)

64 (34.0)

Tender joint count (0-66)

30.5 (14.6)

31.9 (14.3)

Swollen joint count (0-66)

21.4 (11.4)

22.5 (12.1)

C-reactive protein (mg/l)

40.2 (42.4)

40.4 (40.9)

HAQ (0-3)

1.5 (0.6)

1.5 (0.7)

DAS28

6.3 (0.9)

6.3 (0.9)

DXR-MCI (mg/cm2)

0.45 (0.09)

0.45 (0.09)

  1. DMARDs = disease modifying anti-rheumatic drugs; HAQ = Health Assessment Questionnaire; DAS28 = 28-joint disease activity score; DXR = Digital X-ray radiogrammetry; MCI = metacarpal cortical index.